San Carlos, Calif.

Went public 8/3/2000 at $15 per share

Filing Range: 7 mil. shares @ $13 to $15

Shares Outstanding: 28.8 mil. shares

Underwriters: Salomon Smith Barney/Robertson Stephens & Co./U.S.

Bancorp Piper Jaffray

Company Counsel: Pillsbury Madison & Sutro

Manager Counsel: Cravath, Swaine & Moore

Auditor: PricewaterhouseCoopers LLP

The Company:

Focuses on using mouse molecular genetics to unlock the “in vivo” function of novel genes in order to develop new therapeutic targets. The company develops so-called “knockout” mouse clones (mice that lack the specific gene.) Using special technology, the company then determines the impact of that gene on the phenotype, the physical expression of an organism’s genetic composition.

Venture Backers:

Sprout Group

Baccharis Capital Inc.

Boston Millennia Partners

Crossroads Group

DLJ Capital

Financing Rounds:

Number of Round Amt.

Round # Round Date Stage Investors ($ thousands)

1 07/08/1998 6 Early Stage 11500.0

2 01/31/2000 4 Expansion 22549.0


(Data in $ millions)



Total Revenues: $1.2

Net Income: -13.8